CD4 and rheumatoid arthritis: In contrast to the MTX-treated cohort, we found impaired SARS-CoV-2–specific CD4+ memory T cell, IgG+ memory B cell, and neutralizing antibody responses to SARS-CoV-2 vaccination in abatacept-treated RA participants (38, 39).